RHOADS ANN D 4

What Happened Ann D. Rhoads, a director of Repare Therapeutics, disposed of 4,000 common shares on January 28, 2026. The Form 4 reports the disposition as "to the issuer" (not an open-market sale) and lists the per-share consideration as N/A on the form itself; footnotes to the filing state the shares were transferred under the Arrangement Agreement in connection with XenoTherapeutics’ acquisition for $2.20 in cash per share plus one non-transferable contingent value right (CVR) per share — implying cash proceeds of about $8,800 plus CVR(s) for the 4,000 shares.

Key Details

• Transaction date: 2026-01-28; Form filed 2026-01-28.
• Consideration per footnotes: $2.20 cash per share + one CVR per share (Form shows price as N/A).
• Shares disposed: 4,000.
• Implied cash proceeds (per footnote): ~ $8,800 (excluding value of CVR).
• Shares owned after transaction: not disclosed in the provided filing.
• Footnotes: F1/F2 explain the disposition occurred under an Arrangement Agreement in which the Purchaser acquired all outstanding Repare shares for $2.20 cash + one CVR per share.
• Timeliness: filing date matches transaction date; no late filing indicated.

Context A "disposition to the issuer" typically reflects surrendering shares as part of a corporate transaction (here, an acquisition), not a voluntary open-market sale. The CVR is a contingent instrument that may provide additional payment depending on future events; its value is not specified in the Form 4. Such merger-related transfers are routine and should be interpreted differently from insider open-market sales when assessing insider sentiment.